|
|
|
|
||
Anavex Results ....From the call: I like the fact that the Placebo controlled Rett Syndrome RS-002 study is already done - i.e., they have the patient data. Now they are studying the data and expect to release the "top-line" results of this by the end of this year. I'm hoping that they do it before Christmas to get a larger impact. I also like it that the 3-71 initial human data will be released by the end of 2021 also. I think 3-71 is the future of Anavex (4-10 year from now time frame). Interestingly, they discuss using 2-73 and 3-71 together to treat Alzheimer's and dementia. However, they indicate that this is a preliminary idea and they don't have sufficient test data. Using Anavex 2-71 as a prophylactic or preventative medicine for certain patients... We have discussed this on the board that using Anavex 2-73 could be used in the future as a preventative manner. The reason that Anavex 2-73 could be used in this manner is that it is an inexpensive medicine to make. Therefore, it is cost effective for people who have a history of dementia type diseases to use it in a preventative manner. Those patients who are finishing the Alzheimer's trial - Anavex has an extension for 3 years, those patients who want to continue the drug can request it. More than 94% of the people in the study request to continue (or in some cases those who had the placebo to start getting Anavex 2-73). Therefore, 94% + patients will continue the Alzheimer's study as an open label manner. They indicate that at the "right time" they might partner with a large pharma company for the treatment of major indications like Alzheimer's disease and Parkinson's disease. But they won't partner until they get to the point where they can get the most upside from their medications. Overall, a very favorable call..... ======= ======== ========= ======== Summary from Anavex's website: Key Company Updates:
Recent Business Highlights:
Financial Highlights:
|
return to message board, top of board |